Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvecaltamide in Moderate to Severe Essential Tremor
NCT05122650Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of suvecaltamide in essential tremor (ET) (4 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change From Baseline to Week 12 on the TETRAS Composite Outcome Score. Started Dec 2021; status: completed.
02
Drugs
suvecaltamide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT05122650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122650.